It’s our one year anniversary! Chris and Don are away this week so rather than have Matt talk to himself, we thought we’d go back and revisit some of our favorite Amazing and Amusing segments from the past year.
Matt, Chris, and Jen talk about a study of whether low-dose aspirin to prevent vascular events should be weight dependent, the gang revisits placebo effects, and Jen focuses on the empathy of our dogs.
Using two of her own studies on the effects of policy decisions on LGBT mental health as examples, Dr. Julia Raifman talks about how health care providers and others working with LGBT people can improve health by shaping social environments.
Matt, Chris, and Jennifer Rider (our first ever guest host) discuss a pragmatic trial of smoking cessation, examine the pros and cons of surrogate endpoints, and Chris schools us all on horse dentistry.
Matt, Chris, and Don review the literature on whether labelling can reduce food purchase and consumption, the gang discusses a series of trials that were found to have errors, and Chris calculates the sum total of all living things on earth.
Matt, Chris, and Don examine a study that looked at whether a vaccine can treat Type 1 diabetes, the gang discusses the “Loss of Confidence Project," and Matt reports on an N of 1 study that suggests red wine may be good for blood sugar.
Matt, Chris, and Don do their second ever live podcast, exploring a study on the effects of sleep on mortality, the gang discusses a proposal to change the definition of statistical significance, and Chris goes rogue and has three amazing and amusing articles.
Matt, Chris, and Don discuss a new treatment for lung cancer (immunotherapy), the gang discusses a large clinical trial that controversially changed its endpoint, and Chris dives into the world of linguistics (again).
Matt, Chris, and Don look at a drug company antidepressant trial in adolescents that was re-analyzed by different authors who came to different conclusions, the gang discusses the pre-registration movement in psychology, and Matt finds out what happens to all those unreported clinical trials.
Matt, Chris, and Don finally take on one of their own studies and see how it holds up, the gang discusses what to do when your study has flaws, and Chris tells us what happens if you don’t get funding as a junior faculty member.